{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:54:24Z","timestamp":1791122064118,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"National Natural Science Foundation","award":["82473814"],"award-info":[{"award-number":["82473814"]}]},{"name":"Guizhou Science and Technology Department","award":["grant numbers GMULH (2025) 028"],"award-info":[{"award-number":["grant numbers GMULH (2025) 028"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Divers"],"DOI":"10.1007\/s11030-026-11670-8","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T09:26:24Z","timestamp":1784798784000},"page":"7531-7549","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Design, synthesis and\u00a0anti-glioblastoma multiforme activity of\u00a0N-methoxy-2-(pyrimidin-4-ylamino)benzamide derivatives as\u00a0focal adhesion kinase inhibitors"],"prefix":"10.1007","volume":"30","author":[{"given":"Yang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haolin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aoxiang","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,23]]},"reference":[{"key":"11670_CR1","doi-asserted-by":"publisher","first-page":"1522392","DOI":"10.3389\/fimmu.2024.1522392","volume":"15","author":"L Yang","year":"2025","unstructured":"Yang L, Li SJ, Yu L et al (2025) Targeting glycolysis: exploring a new frontier in glioblastoma therapy. Front Immunol 15:1522392. https:\/\/doi.org\/10.3389\/fimmu.2024.1522392","journal-title":"Front Immunol"},{"issue":"7","key":"11670_CR2","doi-asserted-by":"publisher","first-page":"3994","DOI":"10.3390\/curroncol31070296","volume":"31","author":"M Jezierzanski","year":"2024","unstructured":"Jezierzanski M, Nafalska N, Stopyra M et al (2024) Temozolomide (TMZ) in the treatment of glioblastoma multiforme-a literature review and clinical outcomes. Curr Oncol 31(7):3994\u20134002. https:\/\/doi.org\/10.3390\/curroncol31070296","journal-title":"Curr Oncol"},{"issue":"7","key":"11670_CR3","doi-asserted-by":"publisher","first-page":"494","DOI":"10.3390\/cells14070494","volume":"14","author":"JS Tang","year":"2025","unstructured":"Tang JS, Karbhari N, Campian JL (2025) Therapeutic targets in glioblastoma: molecular pathways, emerging strategies, and future directions. Cells 14(7):494 https:\/\/doi.org\/10.3390\/cells14070494","journal-title":"Cells"},{"issue":"1","key":"11670_CR4","doi-asserted-by":"publisher","first-page":"E73","DOI":"10.1016\/j.ijrobp.2019.06.2329","volume":"105","author":"BT Cooper","year":"2019","unstructured":"Cooper BT, Shenker RF, Oh C et al (2019) A prospective observational study correlating peripheral biomarkers associated with changes to the blood-brain barrier and tumor volume in patients treated with radiation for intracranial metastases. Int J Radiat Oncol Biol Phys 105(1):E73. https:\/\/doi.org\/10.1016\/j.ijrobp.2019.06.2329","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"11670_CR5","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.apsb.2014.03.001","volume":"4","author":"XL Wei","year":"2014","unstructured":"Wei XL, Chen XS, Ying M et al (2014) Brain tumor-targeted drug delivery strategies. Acta Pharm Sin B 4(3):193\u2013201. https:\/\/doi.org\/10.1016\/j.apsb.2014.03.001","journal-title":"Acta Pharm Sin B"},{"key":"11670_CR6","doi-asserted-by":"publisher","first-page":"S392","DOI":"10.1016\/j.annonc.2023.09.1694","volume":"34","author":"MV Villar","year":"2023","unstructured":"Villar MV, Sanchez JMS, Garcia VM et al (2023) Trotabresib (CC-90010) combined with concomitant temozolomide (TMZ) plus radiotherapy (RT) and adjuvant TMZ in patients (pts) with newly diagnosed primary glioblastoma (ndGBM): Updated results from a phase Ib\/II study. Ann Oncol 34:S392\u2013S392. https:\/\/doi.org\/10.1016\/j.annonc.2023.09.1694","journal-title":"Ann Oncol"},{"issue":"16","key":"11670_CR7","doi-asserted-by":"publisher","first-page":"2044","DOI":"10.1200\/JCO.2022.40.16_suppl.2044","volume":"40","author":"LB Nabors","year":"2022","unstructured":"Nabors LB, Lobbous M, Lamb LS et al (2022) Phase I study of drug-resistant immunotherapy (DRI) with gene-modified autologous \u03b3\u03b4 T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide (TMZ). J Clin Oncol 40(16):2044. https:\/\/doi.org\/10.1200\/JCO.2022.40.16_suppl.2044","journal-title":"J Clin Oncol"},{"key":"11670_CR8","doi-asserted-by":"publisher","first-page":"104694","DOI":"10.1016\/j.jddst.2023.104694","volume":"86","author":"A Mishra","year":"2023","unstructured":"Mishra A, Kumar R, Mishra J et al (2023) Strategies facilitating the permeation of nanoparticles through blood-brain barrier: an insight towards the development of brain-targeted drug delivery system. J Drug Deliv Sci Technol 86:104694 https:\/\/doi.org\/10.1016\/j.jddst.2023.104694","journal-title":"J Drug Deliv Sci Technol"},{"key":"11670_CR9","doi-asserted-by":"publisher","first-page":"116246","DOI":"10.1016\/j.bcp.2024.116246","volume":"224","author":"M Yang","year":"2024","unstructured":"Yang M, Xiang H, Luo GS (2024) Targeting focal adhesion kinase (FAK) for cancer therapy: FAK inhibitors, FAK-based dual-target inhibitors and PROTAC degraders. Biomed Pharmacother 224:116246 https:\/\/doi.org\/10.1016\/j.bcp.2024.116246","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"11670_CR10","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/ijc.26351","volume":"131","author":"A Serrels","year":"2012","unstructured":"Serrels A, McLeod K, Canel M et al (2012) The role of focal adhesion kinase catalytic activity on the proliferation and migration of squamous cell carcinoma cells. Int J Cancer 131(2):287\u2013297. https:\/\/doi.org\/10.1002\/ijc.26351","journal-title":"Int J Cancer"},{"issue":"1","key":"11670_CR11","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s40164-023-00446-7","volume":"12","author":"XM Tan","year":"2023","unstructured":"Tan XM, Yan YH, Song B et al (2023) Focal adhesion kinase: from biological functions to therapeutic strategies. Exp Hematol Oncol 12(1):83. https:\/\/doi.org\/10.1186\/s40164-023-00446-7","journal-title":"Exp Hematol Oncol"},{"key":"11670_CR12","doi-asserted-by":"publisher","first-page":"101329","DOI":"10.1016\/j.drup.2025.101329","volume":"84","author":"W Gao","year":"2026","unstructured":"Gao W, Huang JL, Deng K et al (2026) Endothelial cells sense temozolomide resistance to facilitate monocyte-derived macrophage infiltration in glioblastoma. Drug Resist Updat 84:101329. https:\/\/doi.org\/10.1016\/j.drup.2025.101329","journal-title":"Drug Resist Updat"},{"key":"11670_CR13","doi-asserted-by":"publisher","first-page":"122708","DOI":"10.1016\/j.biomaterials.2024.122708","volume":"311","author":"JA Li","year":"2024","unstructured":"Li JA, Yang J, Jiang SP et al (2024) Targeted reprogramming of tumor-associated macrophages for overcoming glioblastoma resistance to chemotherapy and immunotherapy. Biomater 311:122708. https:\/\/doi.org\/10.1016\/j.biomaterials.2024.122708","journal-title":"Biomater"},{"issue":"1","key":"11670_CR14","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s40478-024-01754-7","volume":"12","author":"F Yalcin","year":"2024","unstructured":"Yalcin F, Haneke H, Efe IE et al (2024) Tumor associated microglia\/macrophages utilize GPNMB to promote tumor growth and alter immune cell infiltration in glioma. Acta Neuropathol Commun 12(1):50. https:\/\/doi.org\/10.1186\/s40478-024-01754-7","journal-title":"Acta Neuropathol Commun"},{"issue":"1","key":"11670_CR15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/s41698-025-00920-x","volume":"9","author":"WW Zhao","year":"2025","unstructured":"Zhao WW, Zhang Z, Xie MY et al (2025) Exploring tumor-associated macrophages in glioblastoma: from diversity to therapy. NPJ Precis Oncol 9(1):126. https:\/\/doi.org\/10.1038\/s41698-025-00920-x","journal-title":"NPJ Precis Oncol"},{"issue":"13","key":"11670_CR16","doi-asserted-by":"publisher","first-page":"CT019","DOI":"10.1158\/1538-7445.am2021-ct019","volume":"81","author":"MG Krebs","year":"2021","unstructured":"Krebs MG, Shinde R, Rahman RA et al (2021) A phase I trial of the combination of the dual RAF-MEK inhibitor VS-6766 and the FAK inhibitor defactinib: evaluation of efficacy in KRAS mutated NSCLC. Cancer Res 81(13):CT019\u2013CT019. https:\/\/doi.org\/10.1158\/1538-7445.am2021-ct019","journal-title":"Cancer Res"},{"key":"11670_CR17","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/s0959-8049(14)70339-9","volume":"50","author":"T Doi","year":"2014","unstructured":"Doi T, Lin CC, Ohtsu A et al (2014) A phase I dose-finding study of BI 853520, a potent and selective inhibitor of focal adhesion kinase (FAK), in Japanese and Taiwanese patients with advanced or metastatic solid tumors. Eur J Cancer 50:72\u201372. https:\/\/doi.org\/10.1016\/s0959-8049(14)70339-9","journal-title":"Eur J Cancer"},{"key":"11670_CR18","doi-asserted-by":"publisher","first-page":"116226","DOI":"10.1016\/j.bmc.2021.116226","volume":"41","author":"HB Hu","year":"2021","unstructured":"Hu HB, Bajorath J (2021) Systematic assessment of structure-promiscuity relationships between different types of kinase inhibitors. Bioorg Med Chem 41:116226. https:\/\/doi.org\/10.1016\/j.bmc.2021.116226","journal-title":"Bioorg Med Chem"},{"issue":"7","key":"11670_CR19","doi-asserted-by":"publisher","first-page":"3749","DOI":"10.1080\/07391102.2023.2301055","volume":"43","author":"Y Liu","year":"2025","unstructured":"Liu Y, Tong J-B, Gao P et al (2025) Combining QSAR techniques, molecular docking, and molecular dynamics simulations to explore anti-tumor inhibitors targeting Focal Adhesion Kinase. J Biomol Struct Dyn 43(7):3749\u20133765. https:\/\/doi.org\/10.1080\/07391102.2023.2301055","journal-title":"J Biomol Struct Dyn"},{"issue":"13","key":"11670_CR20","doi-asserted-by":"publisher","first-page":"5965","DOI":"10.1080\/07391102.2021.1875880","volume":"40","author":"P Shirvani","year":"2022","unstructured":"Shirvani P, Fassihi A (2022) In silico design of novel FAK inhibitors using integrated molecular docking, 3D-QSAR and molecular dynamics simulation studies. J Biomol Struct Dyn 40(13):5965\u20135982. https:\/\/doi.org\/10.1080\/07391102.2021.1875880","journal-title":"J Biomol Struct Dyn"},{"issue":"27","key":"11670_CR21","doi-asserted-by":"publisher","first-page":"12816","DOI":"10.1039\/d3nj02471g","volume":"47","author":"S El Bahi","year":"2023","unstructured":"El Bahi S, Boutalaka M, El Alaouy MA et al (2023) Computational investigation of novel pyrimidine derivatives as potent FAK inhibitors via 3D-QSAR, molecular docking, molecular dynamics simulation and retrosynthesis. New J Chem 47(27):12816\u201312829. https:\/\/doi.org\/10.1039\/d3nj02471g","journal-title":"New J Chem"},{"issue":"1","key":"11670_CR22","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1186\/s13065-024-01316-x","volume":"18","author":"Y Zhao","year":"2024","unstructured":"Zhao Y, He X, Wan Q (2024) Combined machine learning models, docking analysis, ADMET studies and molecular dynamics simulations for the design of novel FAK inhibitors against glioblastoma. BMC Chem 18(1):203. https:\/\/doi.org\/10.1186\/s13065-024-01316-x","journal-title":"BMC Chem"},{"issue":"4","key":"11670_CR23","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s11030-024-10839-3","volume":"28","author":"NT Hang","year":"2024","unstructured":"Hang NT, My TTK, Van Anh LT et al (2024) Identification of potential FAK inhibitors using mol2vec molecular descriptor-based QSAR, molecular docking, ADMET study, and molecular dynamics simulation. Mol Divers 28(4):2163\u20132175. https:\/\/doi.org\/10.1007\/s11030-024-10839-3","journal-title":"Mol Divers"},{"key":"11670_CR24","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.biopha.2016.02.020","volume":"80","author":"V Thiyagarajan","year":"2016","unstructured":"Thiyagarajan V, Lin SH, Chang YC et al (2016) Identification of novel FAK and S6K1 dual inhibitors from natural compounds via ADMET screening and molecular docking. Biomed Pharmacother 80:52\u201362. https:\/\/doi.org\/10.1016\/j.biopha.2016.02.020","journal-title":"Biomed Pharmacother"},{"key":"11670_CR25","doi-asserted-by":"publisher","first-page":"138301","DOI":"10.1016\/j.molstruc.2024.138301","volume":"1311","author":"S Ayaz","year":"2024","unstructured":"Ayaz S, Gupta S, Singh R et al (2024) Combined computational and synthetic strategies for the development of potent pyrazolo-pyridine derivatives as anticancer agents. J Mol Struct 1311:138301. https:\/\/doi.org\/10.1016\/j.molstruc.2024.138301","journal-title":"J Mol Struct"},{"key":"11670_CR26","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2174\/1573409914666181003153249","volume":"15","author":"V Asati","year":"2019","unstructured":"Asati V, Ghode P, Bajaj S et al (2019) 3D-QSAR and molecular docking studies on oxadiazole substituted benzimidazole derivatives: validation of experimental inhibitory potencies towards COX-2. Curr Comput Aided Drug Des 15:277\u2013293. https:\/\/doi.org\/10.2174\/1573409914666181003153249","journal-title":"Curr Comput Aided Drug Des"},{"key":"11670_CR27","doi-asserted-by":"publisher","first-page":"e202405425","DOI":"10.1002\/slct.202405425","volume":"10","author":"V Asati","year":"2025","unstructured":"Asati V, Gupta S, Baweja GS et al (2025) Combined computational techniques for discovery of novel pyrazolo[3,4-d]pyrimidine derivatives as PAK1 inhibitors. ChemistrySelect 10:e202405425. https:\/\/doi.org\/10.1002\/slct.202405425","journal-title":"ChemistrySelect"},{"key":"11670_CR28","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1007\/s00044-016-1577-z","volume":"25","author":"V Asati","year":"2016","unstructured":"Asati V, Bharti SK (2016) QSAR studies for some thiazolidine-2,4-dione derivatives as PIM-2 kinase inhibitors. Med Chem Res 25:1329\u20131339. https:\/\/doi.org\/10.1007\/s00044-016-1577-z","journal-title":"Med Chem Res"},{"key":"11670_CR29","doi-asserted-by":"publisher","first-page":"e202500263","DOI":"10.1002\/cmdc.202500263","volume":"20","author":"A Ragshaniya","year":"2025","unstructured":"Ragshaniya A, Maity S, Kumar L et al (2025) Adamantane-appended 1,2,3-triazole hybrids: synthesis and \u03b1-glucosidase inhibition studies through experimental and in silico approach. ChemMedChem 20:e202500263. https:\/\/doi.org\/10.1002\/cmdc.202500263","journal-title":"ChemMedChem"},{"key":"11670_CR30","doi-asserted-by":"publisher","first-page":"113768","DOI":"10.1016\/j.ejmech.2021.113768","volume":"225","author":"OM Soltan","year":"2021","unstructured":"Soltan OM, Shoman ME, Abdel-Aziz SA et al (2021) Molecular hybrids: a five-year survey on structures of multiple targeted hybrids of protein kinase inhibitors for cancer therapy. Eur J Med Chem 225:113768. https:\/\/doi.org\/10.1016\/j.ejmech.2021.113768","journal-title":"Eur J Med Chem"},{"issue":"4","key":"11670_CR31","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1080\/17460441.2024.2322990","volume":"19","author":"P de Sena Murteira Pinheiro","year":"2024","unstructured":"de Sena Murteira Pinheiro P, Franco LS, Montagnoli TL, Fraga CAM (2024) Molecular hybridization: a powerful tool for multitarget drug discovery. Expert Opin Drug Discov 19(4):451\u2013470. https:\/\/doi.org\/10.1080\/17460441.2024.2322990","journal-title":"Expert Opin Drug Discov"},{"issue":"7","key":"11670_CR32","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1158\/1538-7445.Am2023-3100","volume":"83","author":"A Fistrovich","year":"2023","unstructured":"Fistrovich A, Tandon V, Cabel C et al (2023) The development of pleotropic small molecule kinase inhibitors (SKMIs) for the treatment of glioblastoma multiforme (GBM). Cancer Res 83(7):3100\u20133100. https:\/\/doi.org\/10.1158\/1538-7445.Am2023-3100","journal-title":"Cancer Res"},{"issue":"5","key":"11670_CR33","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2174\/1871520622666220701113204","volume":"23","author":"I Rani","year":"2023","unstructured":"Rani I, Kaur N, Goyal A, Sharma M (2023) An appraisal on synthetic and medicinal aspects of fused pyrimidines as anti neoplastic agents. Anticancer Agents Med Chem 23(5):525\u2013561. https:\/\/doi.org\/10.2174\/1871520622666220701113204","journal-title":"Anticancer Agents Med Chem"},{"issue":"23","key":"11670_CR34","doi-asserted-by":"publisher","first-page":"14560","DOI":"10.1021\/acs.jmedchem.0c01947","volume":"63","author":"WG Xiang","year":"2020","unstructured":"Xiang WG, Wang SM (2020) Selectively targeting tropomyosin receptor kinase A (TRKA) via PROTACs. J Med Chem 63(23):14560\u201314561. https:\/\/doi.org\/10.1021\/acs.jmedchem.0c01947","journal-title":"J Med Chem"},{"key":"11670_CR35","doi-asserted-by":"publisher","first-page":"v108","DOI":"10.1093\/neuonc\/noad179.0410","volume":"25","author":"K Inai","year":"2023","unstructured":"Inai K, Hamabe-Horiike T, Ono M et al (2023) Curcumin analogs exhibit anti-tumor activity against glioblastoma at lower concentrations than curcumin. Neuro-Oncol 25:v108. https:\/\/doi.org\/10.1093\/neuonc\/noad179.0410","journal-title":"Neuro-Oncol"},{"issue":"19","key":"11670_CR36","doi-asserted-by":"publisher","first-page":"4775","DOI":"10.3390\/cancers15194775","volume":"15","author":"P Franco","year":"2023","unstructured":"Franco P, Camerino I, Merlino F et al (2023) \u03b1V-integrin-dependent inhibition of glioblastoma cell migration, invasion and vasculogenic mimicry by the uPAcyclin decapeptide. Cancers (Basel) 15(19):4775. https:\/\/doi.org\/10.3390\/cancers15194775","journal-title":"Cancers (Basel)"},{"key":"11670_CR37","doi-asserted-by":"publisher","first-page":"117288","DOI":"10.1016\/j.ejmech.2025.117288","volume":"286","author":"Y Wei","year":"2025","unstructured":"Wei Y, He XL, Long ZW et al (2025) Discovery of noncovalent diaminopyrimidine-based inhibitors for glioblastoma via a dual FAK\/DNA targeting strategy. Eur J Med Chem 286:117288. https:\/\/doi.org\/10.1016\/j.ejmech.2025.117288","journal-title":"Eur J Med Chem"},{"key":"11670_CR38","doi-asserted-by":"publisher","first-page":"7658899","DOI":"10.1155\/2022\/7658899","volume":"1","author":"SA Alharthy","year":"2022","unstructured":"Alharthy SA, Tabrez S, Mirza AA et al (2022) (2022) Sugiol suppresses the proliferation of human u87 glioma cells via induction of apoptosis and cell cycle arrest. Evid-Based Compl Alt 1:7658899. https:\/\/doi.org\/10.1155\/2022\/7658899","journal-title":"Evid-Based Compl Alt"},{"issue":"6","key":"11670_CR39","doi-asserted-by":"publisher","first-page":"3036","DOI":"10.1021\/acs.jmedchem.8b01925","volume":"62","author":"MR Bauer","year":"2019","unstructured":"Bauer MR, Mackey MD (2019) Electrostatic complementarity as a fast and effective tool to optimize binding and selectivity of protein-ligand complexes. J Med Chem 62(6):3036\u20133050. https:\/\/doi.org\/10.1021\/acs.jmedchem.8b01925","journal-title":"J Med Chem"},{"key":"11670_CR40","doi-asserted-by":"publisher","first-page":"101292","DOI":"10.1016\/j.swevo.2023.101292","volume":"78","author":"J Zhou","year":"2023","unstructured":"Zhou J, Yang ZF, He Y et al (2023) A novel molecular docking program based on a multi-swarm competitive algorithm. Swarm Evol Comput 78:101292. https:\/\/doi.org\/10.1016\/j.swevo.2023.101292","journal-title":"Swarm Evol Comput"},{"issue":"3","key":"11670_CR41","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1021\/acs.jctc.2c01194","volume":"19","author":"JA Wang","year":"2023","unstructured":"Wang JA, Miao YL (2023) Ligand gaussian accelerated molecular dynamics 2 (LiGaMD2): improved calculations of ligand binding thermodynamics and kinetics with closed protein pocket. J Chem Theory Comput 19(3):733\u2013745. https:\/\/doi.org\/10.1021\/acs.jctc.2c01194","journal-title":"J Chem Theory Comput"},{"key":"11670_CR42","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.csbj.2024.12.017","volume":"27","author":"C Vorreiter","year":"2025","unstructured":"Vorreiter C, Robaa D, Sippl W (2025) Predicting fragment binding modes using customized Lennard-Jones potentials in short molecular dynamics simulations. Comput Struct Biotechnol J 27:102\u2013116. https:\/\/doi.org\/10.1016\/j.csbj.2024.12.017","journal-title":"Comput Struct Biotechnol J"},{"key":"11670_CR43","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.biopha.2017.03.041","volume":"90","author":"Y Liu","year":"2017","unstructured":"Liu Y, Zhang N, Cao QJ et al (2017) The effects of propofol on the growth behavior of hepatoma xenografts in Balb\/c mice. Biomed Pharmacother 90:47\u201352. https:\/\/doi.org\/10.1016\/j.biopha.2017.03.041","journal-title":"Biomed Pharmacother"},{"key":"11670_CR44","doi-asserted-by":"publisher","first-page":"106792","DOI":"10.1016\/j.bioorg.2023.106792","volume":"140","author":"ZW Long","year":"2023","unstructured":"Long ZW, Zuo YQ, Li RR et al (2023) Design, synthesis and biological evaluation of 4-arylamino-pyrimidine derivatives as focal adhesion kinase inhibitors. Bioorg Chem 140:106792. https:\/\/doi.org\/10.1016\/j.bioorg.2023.106792","journal-title":"Bioorg Chem"},{"key":"11670_CR45","doi-asserted-by":"publisher","first-page":"1604661","DOI":"10.3389\/fphar.2025.1604661","volume":"16","author":"LH Piao","year":"2025","unstructured":"Piao LH, Gao Y, Su YY et al (2025) Targeted degradation of EGFR 19Del by PROTACs suppresses tumor growth in non-small-cell lung cancer. Front Pharmacol 16:1604661. https:\/\/doi.org\/10.3389\/fphar.2025.1604661","journal-title":"Front Pharmacol"},{"key":"11670_CR46","doi-asserted-by":"publisher","first-page":"115752","DOI":"10.1016\/j.ejmech.2023.115752","volume":"260","author":"G Jia","year":"2023","unstructured":"Jia G, Qi KJ, Hou BG et al (2023) Design, synthesis, and biological evaluation of novel HDAC\/CD13 dual inhibitors for the treatment of cancer. Eur J Med Chem 260:115752. https:\/\/doi.org\/10.1016\/j.ejmech.2023.115752","journal-title":"Eur J Med Chem"},{"issue":"4","key":"11670_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s12276-019-0241-3","volume":"51","author":"J Lee","year":"2019","unstructured":"Lee J, Jo DH, Kim JH et al (2019) Development of a patient-derived xenograft model of glioblastoma via intravitreal injection in mice. Exp Mol Med 51(4):1\u20139. https:\/\/doi.org\/10.1038\/s12276-019-0241-3","journal-title":"Exp Mol Med"},{"issue":"1","key":"11670_CR48","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1186\/s40478-025-02105-w","volume":"13","author":"AE Yuzhalin","year":"2025","unstructured":"Yuzhalin AE (2025) New experimental therapies for glioblastoma: a review of preclinical research. Acta Neuropathol Commun 13(1):199. https:\/\/doi.org\/10.1186\/s40478-025-02105-w","journal-title":"Acta Neuropathol Commun"},{"issue":"21","key":"11670_CR49","doi-asserted-by":"publisher","first-page":"11259","DOI":"10.1021\/acs.jctc.5c01114","volume":"21","author":"GJ Bekker","year":"2025","unstructured":"Bekker GJ, Fukunishi Y, Higo J et al (2025) Assessment of RNA force fields for dynamic docking of small molecules using multicanonical Md simulations. J Chem Theory Comput 21(21):11259\u201311270. https:\/\/doi.org\/10.1021\/acs.jctc.5c01114","journal-title":"J Chem Theory Comput"},{"issue":"8","key":"11670_CR50","doi-asserted-by":"publisher","first-page":"375","DOI":"10.3390\/md22080375","volume":"22","author":"JQ Chen","year":"2024","unstructured":"Chen JQ, Li X, Tao JH et al (2024) Identification of marine-derived SLC7A11 inhibitors: molecular docking, structure-based virtual screening, cytotoxicity prediction, and molecular dynamics simulation. Mar Drugs 22(8):375 https:\/\/doi.org\/10.3390\/md22080375","journal-title":"Mar Drugs"},{"issue":"5","key":"11670_CR51","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.3390\/molecules29051144","volume":"29","author":"A Salamat","year":"2024","unstructured":"Salamat A, Kosar N, Mohyuddin A et al (2024) SAR, molecular docking and molecular dynamic simulation of natural inhibitors against SARS-CoV-2 Mpro spike protein. Molecules 29(5):1144. https:\/\/doi.org\/10.3390\/molecules29051144","journal-title":"Molecules"},{"issue":"11","key":"11670_CR52","doi-asserted-by":"publisher","first-page":"3076","DOI":"10.1021\/ci400450h","volume":"53","author":"Q Liu","year":"2013","unstructured":"Liu Q, Kwoh CK, Li JY (2013) Binding affinity prediction for protein-ligand complexes based on \u03b2 contacts and B factor. J Chem Inf Model 53(11):3076\u20133085. https:\/\/doi.org\/10.1021\/ci400450h","journal-title":"J Chem Inf Model"},{"issue":"1","key":"11670_CR53","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s13321-024-00918-w","volume":"16","author":"A Ivanova","year":"2024","unstructured":"Ivanova A, Mokshyna O, Polishchuk P (2024) StreaMD: the toolkit for high-throughput molecular dynamics simulations. J Cheminform 16(1):123. https:\/\/doi.org\/10.1186\/s13321-024-00918-w","journal-title":"J Cheminform"},{"key":"11670_CR54","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.jpdc.2021.07.006","volume":"157","author":"GN Barreales","year":"2021","unstructured":"Barreales GN, Novalbos M, Otaduy MA et al (2021) MDScale: scalable multi-GPU bonded and short-range molecular dynamics. J Parallel Distrib Comput 157:243\u2013255. https:\/\/doi.org\/10.1016\/j.jpdc.2021.07.006","journal-title":"J Parallel Distrib Comput"}],"container-title":["Molecular Diversity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11670-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11030-026-11670-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11030-026-11670-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T13:47:11Z","timestamp":1791121631000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11030-026-11670-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,23]]},"references-count":54,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["11670"],"URL":"https:\/\/doi.org\/10.1007\/s11030-026-11670-8","relation":{},"ISSN":["1573-501X"],"issn-type":[{"value":"1573-501X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,23]]},"assertion":[{"value":"27 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}